Epoch Investment Partners Inc. Cuts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Epoch Investment Partners Inc. reduced its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 41.6% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 202,267 shares of the specialty pharmaceutical company’s stock after selling 144,069 shares during the period. Epoch Investment Partners Inc.’s holdings in Supernus Pharmaceuticals were worth $6,899,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $33,000. Quadrant Capital Group LLC lifted its stake in Supernus Pharmaceuticals by 1,117.6% in the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 1,330 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Supernus Pharmaceuticals during the 1st quarter worth approximately $43,000. Covestor Ltd grew its holdings in Supernus Pharmaceuticals by 15.3% during the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 358 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Supernus Pharmaceuticals during the 1st quarter worth approximately $129,000.

Supernus Pharmaceuticals Stock Up 0.2 %

NASDAQ SUPN opened at $30.75 on Monday. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $35.44. The stock has a market capitalization of $1.69 billion, a PE ratio of -106.03 and a beta of 0.91. The firm has a 50 day moving average of $27.52 and a two-hundred day moving average of $29.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.